Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MONARCH: STK-001 in Children and Adolescents With Dravet Syndrome
NCT04442295Phase 2Completed
- Sponsor
- Stoke Therapeutics
- Start
- Jun 2020
- Primary completion
- Nov 2023
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 2, open-label trial of zorevunersen in Dravet syndrome (2 arms), sponsored by Stoke Therapeutics. Primary endpoints: Safety and Tolerability of single and multiple doses of STK-001, Pharmacokinetic Parameters and 1 more. Started Jun 2020; status: completed.
02
Drugs
zorevunersen
03
Conditions
Dravet syndrome
Beyond the preview
Go deeper on NCT04442295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04442295.